Ipsen's rare genetic disorder drug Sohonos and Biogen's ALS drug Qalsody share a common story: in their clinical trials, each was initially flagged for futility, indicating a low likelihood of success. However, subsequent analyses of the full datasets demonstrated meaningful benefits, and they ultimately received regulatory approval.
InflaRx N.V. (IFRX), the company we are profiling today, is also facing a comparable situation with its phase 3 study of Vilobelimab in pyoderma gangrenosum (PG).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com